Effect of gliclazide on cardiovascular risk factors involved in split-dose streptozotocin induced neonatal rat model: a chronic study
Journal: International Journal of Basic & Clinical Pharmacology (Vol.1, No. 3)Publication Date: 2012-12-01
Authors : I. Mohammed Salman Naseeruddin Inamdar;
Page : 196-201
Keywords : n-STZ rat model; streptozotocin; gliclazide; diabetes; hypertension; cardiovascular risk factors;
Abstract
Background: The present study aimed at evaluating the effect of gliclazide on cardiovascular risk factors involved in type 2 diabetes mellitus using n-STZ rat model on a long term basis. Methods: The diabetic model was developed using a split dose of streptozotocin (50 mg/kg) intraperitoneally on 2nd and 3rd postnatal days. The diabetic rats were treated orally with gliclazide suspension at the dose of 10 mg/kg for 90 days. Cardiovascular risk factors such as systolic blood pressure, heart rate, lipid profile, creatine kinase and lactate dehydrogenase were evaluated at regular intervals along with fasting blood glucose (FBG) and oral glucose tolerance test. Results: Gliclazide did not alter FBG however improved the impaired glucose tolerance. The gliclazide treated rats did not develop hypertension and there was a significant difference (p
Other Latest Articles
- Comparison of the efficacy and safety of norethisterone vs. combined oral contraceptive pills for the management of puberty menorrhagia
- Prescription auditing and drug utilization pattern in a tertiary care teaching hospital of western UP
- Study of interaction of nifedipine with haloperidol on conditioned avoidance response and catalepsy in rats
- Comparative evaluation of antihypertensive drugs in the management of pregnancy-induced hypertension
- Lipid lowering and antioxidant potential of Asparagus racemosus in hyperlipidemic rats
Last modified: 2013-03-02 19:30:29